Nicorandil + Standard Treatment
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Stable Angina
Conditions
Stable Angina, Coronary Disease
Trial Timeline
Sep 1, 2011 → May 1, 2014
NCT ID
NCT01396395About Nicorandil + Standard Treatment
Nicorandil + Standard Treatment is a approved stage product being developed by Merck for Stable Angina. The current trial status is completed. This product is registered under clinical trial identifier NCT01396395. Target conditions include Stable Angina, Coronary Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01396395 | Approved | Completed |
Competing Products
20 competing products in Stable Angina
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Atorvastatin 20mg loading + Atorvastatin 80mg loading | Yuhan | Approved | 85 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Epoetin Alfa + Roxadustat | Astellas Pharma | Phase 3 | 77 |
| TRC041266 + Placebo | Torrent Pharmaceuticals | Phase 3 | 77 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| budesonide/formoterol + formoterol | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Clopidogrel + Aspirin | AstraZeneca | Phase 2 | 52 |
| Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor) | AstraZeneca | Approved | 85 |
| TC-5214 + Placebo | AstraZeneca | Phase 1 | 33 |
| ticagrelor + clopidogrel | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| BPS804 + Placebo | Novartis | Phase 2 | 52 |
| CLR325 | Novartis | Phase 2 | 52 |
| Erenumab + Placebo | Amgen | Phase 2 | 51 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| ranolazine + placebo | Gilead Sciences | Approved | 84 |